MX2023002109A - Inhibidores virales. - Google Patents

Inhibidores virales.

Info

Publication number
MX2023002109A
MX2023002109A MX2023002109A MX2023002109A MX2023002109A MX 2023002109 A MX2023002109 A MX 2023002109A MX 2023002109 A MX2023002109 A MX 2023002109A MX 2023002109 A MX2023002109 A MX 2023002109A MX 2023002109 A MX2023002109 A MX 2023002109A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
viral
compound
viral inhibitors
Prior art date
Application number
MX2023002109A
Other languages
English (en)
Spanish (es)
Inventor
Ijeoma Uchegbu
Andreas Schatzlein
Krzysztof Pyrc
Aleksandra Milewska
Duran Emilia Barreto
Original Assignee
Nanomerics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2013221.3A external-priority patent/GB202013221D0/en
Priority claimed from GBGB2019097.1A external-priority patent/GB202019097D0/en
Priority claimed from GBGB2105404.4A external-priority patent/GB202105404D0/en
Application filed by Nanomerics Ltd filed Critical Nanomerics Ltd
Publication of MX2023002109A publication Critical patent/MX2023002109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023002109A 2020-08-24 2021-08-24 Inhibidores virales. MX2023002109A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2013221.3A GB202013221D0 (en) 2020-08-24 2020-08-24 Viral inhibitors
GBGB2019097.1A GB202019097D0 (en) 2020-12-03 2020-12-03 Viral inhibitors
GBGB2105404.4A GB202105404D0 (en) 2021-04-15 2021-04-15 Viral inhibitors
PCT/GB2021/052199 WO2022043678A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Publications (1)

Publication Number Publication Date
MX2023002109A true MX2023002109A (es) 2023-07-13

Family

ID=77655566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002109A MX2023002109A (es) 2020-08-24 2021-08-24 Inhibidores virales.

Country Status (8)

Country Link
US (1) US20230330132A1 (https=)
EP (1) EP4199937A1 (https=)
JP (1) JP2023538449A (https=)
CN (1) CN116367843A (https=)
AU (1) AU2021333748A1 (https=)
CA (1) CA3192515A1 (https=)
MX (1) MX2023002109A (https=)
WO (1) WO2022043678A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
PL225045B1 (pl) * 2012-05-18 2017-02-28 Univ Jagiellonski Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Also Published As

Publication number Publication date
CN116367843A (zh) 2023-06-30
CA3192515A1 (en) 2022-03-03
WO2022043678A1 (en) 2022-03-03
EP4199937A1 (en) 2023-06-28
JP2023538449A (ja) 2023-09-07
US20230330132A1 (en) 2023-10-19
AU2021333748A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
ZA202211060B (en) Anti-viral compounds and methods for administration thereof
ZA202300259B (en) Compound for the treatment of coronaviral infections
WO2021243007A3 (en) Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses
MX2022013749A (es) Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
RU2020123728A (ru) Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
MX2011003535A (es) Composiciones de virus de herpes bovino-1, vacunas, y metodos.
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2022214678A3 (en) Human metapneumo virus vaccine
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
WO2022240379A3 (en) A stable pharmaceutical composition comprising selexipag
MX2023002109A (es) Inhibidores virales.
PH12022552298A1 (en) Treatment for coronavirus infection and associated cytokine toxicity
WO2021219244A8 (en) 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
MX2022012321A (es) Composiciones viricidas y uso de las mismas.
CA3156680A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
CA3156017A1 (en) IMMUNOGENIC COMPOSITIONS
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
WO2023196832A3 (en) Pharmaceutical composition and method for treatment of human immunodeficiency virus infections
EP4335460A3 (en) Compositions and methods for treating granulomatosis with polyangiitis
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
WO2024245930A3 (en) Inhibitors of expression and/or function
WO2024006971A3 (en) Antimalarial compounds